Aquestive Therapeutics
AQST
46 hedge funds and large institutions have $18.7M invested in Aquestive Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
73% more capital invested
Capital invested by funds: $10.8M → $18.7M (+$7.87M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 45 → 46 (+1)
4.07% less ownership
Funds ownership: 33.87% → 29.79% (-4.1%)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$368K |
| 2 |
VAFP
Vahanian & Associates Financial Planning
Saratoga Springs,
New York
|
+$157K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$147K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$137K |
| 5 |
Man Group
London,
United Kingdom
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$715K |
| 2 |
Renaissance Technologies
New York
|
-$368K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$114K |
| 4 |
D.E. Shaw & Co
New York
|
-$106K |
| 5 |
CAC
Cowen and Company
New York
|
-$80K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| – | -$145 | -128 | -18% |
|
AQST Hedge Fund Activity: Q3 2022 in Review
46 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2022, worth a combined $18.7M — up 73% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AQST positions and 6 closed out — a net gain of 1 holder — while 11 added to existing stakes and 14 trimmed.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $368K. The largest seller was Millennium Management, cutting an estimated $715K.
- 46 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2022, up from 45 in Q2 2022.
- Funds reported $18.7M of Aquestive Therapeutics stock for Q3 2022, up 73% quarter-over-quarter.
- 7 funds opened new Aquestive Therapeutics positions in Q3 2022 and 6 closed out, a net change of +1 holder.
- The largest Aquestive Therapeutics buyer in Q3 2022 was Schonfeld Strategic Advisors, an estimated $368K added.
- The largest Aquestive Therapeutics seller in Q3 2022 was Millennium Management, an estimated $715K sold.
Based on aggregated 13F filings for Q3 2022.